Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clinical Development Against COVID-19

AUG-3387 Active Against All Variants Tested Including the UK (B.1.1.7), South African (B.1.351), Indian (B.1.617.1), and Brazil (P.1) Variants

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.



Please enter your comment!
Please enter your name here